Literature DB >> 2866788

Effects of azepexole and clonidine on baroreceptor mediated reflex bradycardia and physiological tremor in man.

D W Harron, J G Riddell, R G Shanks.   

Abstract

The effects of oral administration of azepexole 10 mg, clonidine 300 micrograms and placebo on baroreceptor mediated reflex bradycardia and physiological tremor were investigated in six healthy volunteers. Both azepexole and clonidine reduced (P less than 0.05) systolic (120.5 +/-2.5 to 105.0 +/- 3.3 mm Hg; 115.8 +/- 2.6 to 104.7 +/- 2.8 mm Hg respectively) and diastolic (52.5 +/- 2.6 to 47.2 +/- 1.4 mmHg; 53.7 +/- 1.6 to 49.0 +/- 1.5 mmHg respectively) pressure when compared to placebo and to pre-treatment values. This reduction in pressure was not accompanied by a change in heart rate. Both azepexole and clonidine enhanced (P less than 0.05) baroreflex sensitivity to increases in systolic arterial pressure with phenylephrine. Clonidine facilitated (P less than 0.05) baroreflex sensitivity during the strain phase of the Valsalva manoeuvre, whereas azepexole reduced it (P less than 0.05). Neither clonidine nor azepexole altered finger tremor when compared to placebo or pre-treatment values. Azepexole produced (P less than 0.05) sedation compared to placebo but not when compared to pre-treatment values. Clonidine caused significant increases in sedation when compared to both placebo and to pre-treatment values. The differences between azepexole and clonidine may be due to the greater specificity of azepexole for the alpha 2-adrenoceptor than clonidine.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2866788      PMCID: PMC1400722          DOI: 10.1111/j.1365-2125.1985.tb05093.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  Clinical pharmacology and pharmacokinetics of clonidine.

Authors:  C T Dollery; D S Davies; G H Draffan; H J Dargie; C R Dean; J L Reid; R A Clare; S Murray
Journal:  Clin Pharmacol Ther       Date:  1976-01       Impact factor: 6.875

2.  Effects of clonidine on biochemical indices of sympathetic function and plasma renin activity in normotensive man.

Authors:  L M Wing; J L Reid; C A Hamilton; P Sever; D S Davies; C T Dollery
Journal:  Clin Sci Mol Med       Date:  1977-07

Review 3.  Central alpha-adrenergic systems as targets for hypotensive drugs.

Authors: 
Journal:  Rev Physiol Biochem Pharmacol       Date:  1978       Impact factor: 5.545

4.  Involvement of adrenergic receptors in central vagus activity.

Authors:  W Kobinger; A Walland
Journal:  Eur J Pharmacol       Date:  1971-09       Impact factor: 4.432

5.  Evidence for a central activation of a vagal cardiodepressor reflex by clonidine.

Authors:  W Kobinger; A Walland
Journal:  Eur J Pharmacol       Date:  1972-08       Impact factor: 4.432

6.  Pharmacodynamic studies with a specific alpha 2-adrenoceptor agonist (BHT-933) in man.

Authors:  P C Rubin; C W Howden; K McLean; J L Reid
Journal:  J Cardiovasc Pharmacol       Date:  1982 Jul-Aug       Impact factor: 3.105

7.  Depression of essential tremor by alpha-adrenergic blockade.

Authors:  J Mai; R B Olsen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1981-12       Impact factor: 10.154

8.  Data acquisition in neurophysiology. A flexible microcomputer system for recording neurophysiological data.

Authors:  H G McAllister; G A Armstrong; R J McClelland; R Linggard
Journal:  Br J Audiol       Date:  1983-11

9.  Effects of oral clonidine on baroreflex function in patients with essential hypertension.

Authors:  G P Guthrie; T A Kotchen
Journal:  Chest       Date:  1983-02       Impact factor: 9.410

10.  Input impedance of the systemic circulation in man.

Authors:  W W Nichols; C R Conti; W E Walker; W R Milnor
Journal:  Circ Res       Date:  1977-05       Impact factor: 17.367

View more
  9 in total

1.  Increased central alpha 2-adrenoceptor sensitivity in panic disorder.

Authors:  D J Nutt
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

2.  The effects of clonidine on cardiovascular responses to standing in healthy volunteers.

Authors:  N J Coupland; J E Bailey; S J Wilson; R Horvath; D Nutt
Journal:  Clin Auton Res       Date:  1995-06       Impact factor: 4.435

3.  Cardiovagal baroreflex gain relates to sensory loss after spinal cord injury.

Authors:  Adina E Draghici; J Andrew Taylor
Journal:  Auton Neurosci       Date:  2020-03-23       Impact factor: 3.145

4.  Enhancement of pressor response to intravenous phenylephrine following oral clonidine medication in awake and anaesthetized patients.

Authors:  S Inomata; T Nishikawa; S Kihara; Y Akiyoshi
Journal:  Can J Anaesth       Date:  1995-02       Impact factor: 5.063

5.  Baroreceptor function in man following peripheral alpha 1- and alpha 2-adrenoceptor stimulation.

Authors:  A H Deering; J G Riddell; R G Shanks; D W Harron
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

6.  The effect of acute and chronic captopril therapy on baroreflex function in man.

Authors:  G B Kondowe; A H Deering; J G Riddell; G D Johnston; D W Harron
Journal:  Br J Clin Pharmacol       Date:  1988-03       Impact factor: 4.335

7.  Effect of oral clonidine premedication on perioperative haemodynamic response and postoperative analgesic requirement for patients undergoing laparoscopic cholecystectomy.

Authors:  Shivinder Singh; Kapil Arora
Journal:  Indian J Anaesth       Date:  2011-01

8.  Clinical Practice: Should we Radically Alter our Sedation of Critical Care Patients, Especially Given the COVID-19 Pandemics?

Authors:  D Longrois; F Petitjeans; O Simonet; M de Kock; M Belliveau; C Pichot; Th Lieutaud; M Ghignone; L Quintin
Journal:  Rom J Anaesth Intensive Care       Date:  2021-01-04

9.  How should dexmedetomidine and clonidine be prescribed in the critical care setting?

Authors:  Dan Longrois; Fabrice Petitjeans; Olivier Simonet; Marc de Kock; Marc Belliveau; Cyrille Pichot; Thomas Lieutaud; Marco Ghignone; Luc Quintin
Journal:  Rev Bras Ter Intensiva       Date:  2022-01-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.